Next Article in Journal
Personomics: The Missing Link in the Evolution from Precision Medicine to Personalized Medicine
Next Article in Special Issue
Novel PAMAM-PEG-Peptide Conjugates for siRNA Delivery Targeted to the Transferrin and Epidermal Growth Factor Receptors
Previous Article in Journal
Value-Based Pricing and Reimbursement in Personalised Healthcare: Introduction to the Basic Health Economics
Article Menu

Export Article

Open AccessReview
J. Pers. Med. 2017, 7(4), 12; https://doi.org/10.3390/jpm7040012

Personalized Nanomedicine: A Revolution at the Nanoscale

1
Sagetis Biotech, 08017 Barcelona, Spain
2
Department of Pharmacy and Pharmaceutic Technology and Physicochemistry, R + D Associated Unit to CSIC, Faculty of Pharmacy and Food Sciences and Institute of Nanosciences and Nanotechnology (IN2UB), University of Barcelona, 08028 Barcelona, Spain; Centro de Investigación Biomédica en Red (CIBER) of Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), 08028 Barcelona, Spain
*
Authors to whom correspondence should be addressed.
Academic Editor: Stephen B. Liggett
Received: 31 August 2017 / Revised: 4 October 2017 / Accepted: 4 October 2017 / Published: 12 October 2017
(This article belongs to the Special Issue Personalized Nanomedicine)
Full-Text   |   PDF [2676 KB, uploaded 16 October 2017]   |  

Abstract

Nanomedicine is an interdisciplinary research field that results from the application of nanotechnology to medicine and has the potential to significantly improve some current treatments. Specifically, in the field of personalized medicine, it is expected to have a great impact in the near future due to its multiple advantages, namely its versatility to adapt a drug to a cohort of patients. In the present review, the properties and requirements of pharmaceutical dosage forms at the nanoscale, so-called nanomedicines, are been highlighted. An overview of the main current nanomedicines in pre-clinical and clinical development is presented, detailing the challenges to the personalization of these therapies. Next, the process of development of novel nanomedicines is described, from their design in research labs to their arrival on the market, including considerations for the design of nanomedicines adapted to the requirements of the market to achieve safe, effective, and quality products. Finally, attention is given to the point of view of the pharmaceutical industry, including regulation issues applied to the specific case of personalized medicine. The authors expect this review to be a useful overview of the current state of the art of nanomedicine research and industrial production, and the future opportunities of personalized medicine in the upcoming years. The authors encourage the development and marketing of novel personalized nanomedicines. View Full-Text
Keywords: personalized nanomedicine; nanotherapeutics; nanodrugs; nanosystems; scale-up; nanomedicines market; stakeholders personalized nanomedicine; nanotherapeutics; nanodrugs; nanosystems; scale-up; nanomedicines market; stakeholders
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Fornaguera, C.; García-Celma, M.J. Personalized Nanomedicine: A Revolution at the Nanoscale. J. Pers. Med. 2017, 7, 12.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Pers. Med. EISSN 2075-4426 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top